Pharma
Cobenfy’s First Year: A Quiet Revolution in Schizophrenia Treatment
The first new mechanism for schizophrenia in 70 years launched in late 2024. Now, as we enter Q1 2026, we have enough data to assess
Updates on therapeutic development, commercial strategy, drug launches, manufacturing, safety insights, and lifecycle management across the pharmaceutical industry.
The first new mechanism for schizophrenia in 70 years launched in late 2024. Now, as we enter Q1 2026, we have enough data to assess
The era of 15% weight loss is over. We are now entering the 30% era. Eli Lilly’s retatrutide has delivered 28.7% weight loss in its
Executive Takeaway The FDA approved 46 novel drugs in 2025, four fewer than 2024’s 50 approvals but still above the historic average of 36 new
The shift from intravenous to subcutaneous drug administration is accelerating across oncology and immunology, fundamentally changing how patients receive treatment and how healthcare systems manage
Merck just scored FDA approval for Keytruda QLEX, a subcutaneous formulation of pembrolizumab that can be administered in 1-2 minutes instead of a 30-minute IV
The obesity drug market is heating up fast, and Pfizer just made a major play. Their acquisition of Metsera for up to $7.3 billion shows
AbbVie just pulled off one of the most successful patent defense strategies in recent pharmaceutical history. By settling with all generic challengers to its blockbuster
In a dramatic reversal that highlights the delicate balance of vaccine development, the FDA has suspended use of the world’s first chikungunya vaccine after recipients
The UK’s National Institute for Health and Care Excellence (NICE) has proposed the most significant overhaul of type 2 diabetes treatment in over a decade,
In a landmark decision that could transform treatment for hundreds of thousands of Americans, the FDA has approved Brinsupri (insmedpirdine) as the first-ever medication specifically